Quantification system for the viral dynamics of a highly pathogenic simian/human immunodeficiency virus based on an in vitro experiment and a mathematical model

Retrovirology

Volumn 9, Issue , 2012, Pages

  Iwami, Shingo ^a,b,c,f   Holder, Benjamin P ^d   Beauchemin, Catherine A A ^d   Morita, Satoru ^e   Tada, Tetsuko ^c   Sato, Kei ^c   Igarashi, Tatsuhiko ^c   Miura, Tomoyuki ^c  

^a JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d RYERSON UNIVERSITY   (Canada)

^e SHIZUOKA UNIVERSITY   (Japan)

^f KYUSHU UNIVERSITY   (Japan)

Author keywords

In vitro experiment; Mathematical model; Quantification of viral dynamics; Simian human immunodeficiency virus; Viral infectiousness

Indexed keywords

ANIMAL CELL; ARTICLE; CELL COUNT; CELL CULTURE; CONTROLLED STUDY; GENE DOSAGE; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; MATHEMATICAL MODEL; NONHUMAN; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; RETROVIRUS; RNA DEGRADATION; SIMIAN IMMUNODEFICIENCY VIRUS; VIRION; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS LOAD; ANIMAL; CELL LINE; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA FASCICULARIS; PATHOGENICITY; T LYMPHOCYTE; THEORETICAL MODEL; VIROLOGY;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

ANIMALS; CELL LINE; HIV-1; MACACA FASCICULARIS; MODELS, THEORETICAL; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES; VIRAL LOAD;

EID: 84857314286     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-9-18     Document Type: Article

References (63)

1. Harouse JM, Gettie A, Tan RC, Blanchard J, Cheng-Mayer C. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 1999, 284:816-819. 10.1126/science.284.5415.816, 10221916.
2. Matsuda K, Inaba K, Fukazawa Y, Matsuyama M, Ibuki K, Horiike M, Saito N, Hayami M, Igarashi T, Miura T. In vivo analysis of a new R5 tropic SHIV generated from the highly pathogenic SHIV-KS661, a derivative of SHIV-89.6. Virology 2010, 399:134-143. 10.1016/j.virol.2010.01.008, 20102777.
3. Nishimura Y, Igarashi T, Donau OK, Buckler-White A, Buckler C, Lafont BA, Goeken RM, Goldstein S, Hirsch VM, Martin MA. Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys explaining their divergent clinical courses. Proc Natl Acad Sci USA 2004, 101:12324-12329. 10.1073/pnas.0404620101, 514404, 15297611.
4. Reimann KA, Li JT, Veazey R, Halloran M, Park IW, Karlsson GB, Sodroski J, Letvin NL. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol 1996, 70:6922-6928. 190741, 8794335.
5. Shinohara K, Sakai K, Ando S, Ami Y, Yoshino N, Takahashi E, Someya K, Suzaki Y, Nakasone T, Sasaki Y, Kaizu M, Lu Y, Honda M. A highly pathogenic simian/human immunodeficiency virus with genetic changes in cynomolgus monkey. J Gen Virol 1999, 80:1231-1240.
6. Kozyrev IL, Ibuki K, Shimada T, Kuwata T, Takemura T, Hayami M, Miura T. Characterization of less pathogenic infectious molecular clones derived from acute-pathogenic SHIV-89.6p stock virus. Virology 2001, 282:6-13. 10.1006/viro.2000.0839, 11259185.
7. Miyake A, Ibuki K, Enose Y, Suzuki H, Horiuchi R, Motohara M, Saito N, Nakasone T, Honda M, Watanabe T, Miura T, Hayami M. Rapid dissemination of a pathogenic simian/human immunodeficiency virus to systemic organs and active replication in lymphoid tissues following intrarectal infection. J Gen Virol 2006, 13:11-20.
8. Inaba K, Fukazawa Y, Matsuda K, Himeno A, Matsuyama M, Ibuki K, Miura Y, Koyanagi Y, Nakajima A, Blumberg RS, Takahashi H, Hayami M, Igarashi T, Miura T. Small intestine CD4+ cell reduction and enteropathy in simian/human immunodeficiency virus KS661-infected rhesus macaques in the presence of low viral load. J Gen Virol 2010, 91:773-781. 10.1099/vir.0.017368-0, 3192539, 19889928.
9. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004, 432:922-924. 10.1038/nature03153, 15602565.
10. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126. 10.1038/373123a0, 7816094.
11. Little SJ, McLean AR, Spina CA, Richman DD, Havlir DV. Viral dynamics of acute HIV-1 infection. J Exp Med 1999, 190:841-850. 10.1084/jem.190.6.841, 2195636, 10499922.
12. Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M, Perelson AS, Ho DD. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol 2003, 77:5037-5038. 10.1128/JVI.77.8.5037-5038.2003, 152136, 12663814.
13. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282:103-107.
14. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, Ho DD. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387:188-191. 10.1038/387188a0, 9144290.
15. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586. 10.1126/science.271.5255.1582, 8599114.
16. Ribeiro RM, Qin L, Chavez LL, Li D, Self SG, Perelson AS. Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection. J Virol 2010, 84:6096-6102. 10.1128/JVI.00127-10, 2876646, 20357090.
17. Stafford MA, Corey L, Cao Y, Daar ES, Ho DD, Perelson AS. Modeling plasma virus concentration during primary HIV infection. J Theor Biol 2000, 203:285-301. 10.1006/jtbi.2000.1076, 10716909.
18. Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS. Kinetics of influenza A virus infection in humans. J Virol 2006, 80:7590-7599. 10.1128/JVI.01623-05, 1563736, 16840338.
19. Beauchemin CA, McSharry JJ, Drusano GL, Nguyen JT, Went GT, Ribeiro RM, Perelson AS. Modeling amantadine treatment of influenza A virus in vitro. J Theor Biol 2008, 254:439-451. 10.1016/j.jtbi.2008.05.031, 2663526, 18653201.
20. Chen HY, Di Mascio M, Perelson AS, Ho DD, Zhang L. Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques. Proc Natl Acad Sci USA 2007, 104:19079-19084. 10.1073/pnas.0707449104, 2141911, 18025463.
21. Dimitrov DS, Willey RL, Sato H, Chang LJ, Blumenthal R, Martin MA. Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol 1993, 67:2182-2190. 240333, 8445728.
22. Dinoso JB, Rabi SA, Blankson JN, Gama L, Mankowski JL, Siliciano RF, Zink MC, Clements JE. A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol 2009, 83:9247-9257. 10.1128/JVI.00840-09, 2738256, 19570871.
23. Igarashi T, Brown C, Azadegan A, Haigwood N, Dimitrov D, Martin MA, Shibata R. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nat Med 1999, 5:211-216. 10.1038/5576, 9930870.
24. Miao H, Hollenbaugh JA, Zand MS, Holden-Wiltse J, Mosmann TR, Perelson AS, Wu H, Topham DJ. Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J Virol 2010, 84:6687-6698. 10.1128/JVI.00266-10, 2903284, 20410284.
25. Mitchell H, Levin D, Forrest S, Beauchemin CA, Tipper J, Knight J, Donart N, Layton RC, Pyles J, Gao P, Harrod KS, Perelson AS, Koster F. Higher level of replication efficiency of 2009 (H1N1) pandemic influenza virus than those of seasonal and avian strains: kinetics from epithelial cell culture and computational modeling. J Virol 2011, 85:1125-1135. 10.1128/JVI.01722-10, 3019989, 21068247.
26. Mohler L, Flockerzi D, Sann H, Reichl U. Mathematical model of influenza A virus production in large-scale microcarrier culture. Biotechnol Bioeng 2005, 90:46-58. 10.1002/bit.20363, 15736163.
27. Nowak MA, Lloyd AL, Vasquez GM, Wiltrout TA, Wahl LM, Bischofberger N, Williams J, Kinter A, Fauci AS, Hirsch VM, Lifson JD. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol 1997, 71:7518-7525. 192098, 9311831.
28. Regoes RR, Barber DL, Ahmed R, Antia R. Estimation of the rate of killing by cytotoxic T lymphocytes in vivo. Proc Natl Acad Sci USA 2007, 104:1599-1603. 10.1073/pnas.0508830104, 1785271, 17242364.
29. Schulze-Horsel J, Schulze M, Agalaridis G, Genzel Y, Reichl U. Infection dynamics and virus-induced apoptosis in cell culture-based influenza vaccine production - Flow cytometry and mathematical modeling. Vaccine 2009, 27:2712-2722. 10.1016/j.vaccine.2009.02.027, 19428884.
30. Funk GA, Fischer M, Joos B, Opravil M, Gunthard H, Huldrych F, Ledergerber B, Bonhoeffer S. Quantification of In Vivo Replicative Capacity of HIV-1 in Different Compartments of Infected Cells. JAIDS 2001, 26:397-404. 10.1097/00126334-200104150-00001, 11391158.
31. Hlavacek WS, Stilianakis NI, Notermans DW, Danner SA, Perelson AS. Influence of follicular dendritic cells on decay of HIV during antiretroviral therapy. Proc Natl Acad Sci USA 2000, 97:10966-10971. 27132, 10995459.
32. Kepler GM, Nguyen HK, Webster-Cyriaque J, Banks HT. A dynamic model for induced reactivation of latent virus. J Theor Biol 2007, 244:451-462. 10.1016/j.jtbi.2006.08.020, 2075089, 17045614.
33. Murray JM, Purcell RH, Wieland SF. The half-life of hepatitis B virions. Hepatology 2006, 44:1117-1121. 10.1002/hep.21364, 17058221.
34. Regoes RR, Antia R, Garber DA, Silvestri G, Feinberg MB, Staprans SI. Roles of target cells and virus-specific cellular immunity in primary simian immunodeficiency virus infection. J Virol 2004, 78:4866-4875. 10.1128/JVI.78.9.4866-4875.2004, 387667, 15078967.
35. Speirs C, van Nimwegen E, Bolton D, Zavolan M, Duvall M, Angleman S, Siegel R, Perelson AS, Lenardo MJ. Analysis of human immunodeficiency virus cytopathicity by using a new method for quantitating viral dynamics in cell culture. J Virol 2005, 79:4025-4032. 10.1128/JVI.79.7.4025-4032.2005, 1061548, 15767404.
36. Stilianakis NI, Boucher CAB, deJong MD, van Leeuwen R, Schuurman R, de Boer RJ. Clinical data sets of HIV1 Reverse transcriptase-resistant mutants explained by a mathematical model. J Virol 1997, 71:161-168. 191036, 8985335.
37. Verotta D, Schaedeli F. Non-linear dynamics modes characterizing long-term virological data from AIDS clinical trials. Math Biosci 2002, 176:163-183. 10.1016/S0025-5564(02)00090-1, 11916507.
38. Nowak MA, May RM. Virus dynamics. 2000, Oxford University Press.
39. Perelson AS. Modeling viral and immune system dynamics. Nat Rev Immunol 2001, 2:28-36.
40. Bangham CRM, Kirkwood TBL. Defective interfering particles: Effects in modulating virus growth and persistence. Virology 1990, 179:821-826. 10.1016/0042-6822(90)90150-P, 2238471.
41. Ma ZM, Stone M, Piatak M, Schweighardt B, Haigwood NL, Montefiori D, Lifson JD, Busch MP, Miller CJ. High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute Simian Immunodeficiency Virus infection. J Virol 2009, 83:3288-3297. 10.1128/JVI.02423-08, 2655556, 19129448.
42. Vaidya NK, Ribeiro RM, Miller CJ, Perelson AS. Viral dynamics during primary Simian Immunodeficiency Virus Infection: Effect of Time-dependent Virus Infectivity. J Virol 2010, 84:4302-4310. 10.1128/JVI.02284-09, 2863724, 20147390.
43. Anderson RM. The Kermack-McKendrick Epidemic Threshold Theorem. Bull Math Biol 1991, 53:3-32. 10.1016/S0092-8240(05)80039-4, 2059740.
44. Brandin E, Thorstensson R, Bonhoeffer S, Albert J. Rapid viral decay in simian immunodeficiency virus-infected macaques receiving quadruple antiretroviral therapy. J Virol 2006, 80:9861-9864. 10.1128/JVI.00394-06, 1617217, 16973590.
45. Eckstein DA, Penn ML, Korin YD, Scripture-Adams DD, Zack JA, Kreisberg JF, Roederer M, Sherman MP, Chin PS, Goldsmith MA. HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues. Immunity 2001, 15:671-682. 10.1016/S1074-7613(01)00217-5, 11672548.
46. Tsai WP, Conley SR, Kung HF, Garrity RR, Nara PL. Preliminary in vitro growth cycle and transmission studies of HIV-1 in an autologous primary cell assay of blood-derived macrophages and peripheral blood mononuclear cells. Virology 1996, 226:205-216. 10.1006/viro.1996.0648, 8955040.
47. Huang AS, Baltimore D. Defective viral particles and viral disease processes. Nature 1970, 226:325-327. 10.1038/226325a0, 5439728.
48. Kwon YJ, Hung G, Anderson WF, Peng CA, Yu H. Determination of infectious retrovirus concentration from colony-forming assay with quantitative analysis. J Virol 2003, 77:5712-5720. 10.1128/JVI.77.10.5712-5720.2003, 154030, 12719564.
49. Rusert P, Fischer M, Joos B, Leemann C, Kuster H, Flepp M, Bonhoeffer S, Gunthard HF, Trkola A. Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol. Virology 2004, 326:113-129. 10.1016/j.virol.2004.05.022, 15262500.
50. Platt EJ, Kozak SL, Durnin JP, Hope TJ, Kabat D. Rapid dissociation of HIV-1 from cultured cells severely limits infectivity assays, causes the inactivation ascribed to entry inhibitors, and masks the inherently high level of infectivity of virions. J Virol 2010, 84:3106-3110. 10.1128/JVI.01958-09, 2826045, 20042508.
51. Thomas JA, Ott DE, Gorelick RJ. Efficiency of Human Immunodeficiency Virus Type 1 Postentry Infection Processes: Evidence against Disproportionate Numbers of Defective Virions. J Virol 2007, 81:4367-4370. 10.1128/JVI.02357-06, 1866140, 17267494.
52. Marcus PI, Ngunjiri JM, Sekellick MJ. Dynamics of biologically active subpopulations of influenza virus: Plaque-forming, noninfectious cell-killing, and defective interfering particles. J Virol 2009, 83:8122-8130. 10.1128/JVI.02680-08, 2715774, 19494019.
53. Izumi T, Io K, Matsui M, Shirakawa K, Shinohara M, Nagai Y, Kawahara M, Kobayashi M, Kondoh H, Misawa N, Koyanagi Y, Uchiyama T, Takaori-Kondo A. HIV-1 viral infectivity factor interacts with TP53 to induce G2 cell cycle arrest and positively regulate viral replication. Proc Natl Acad Sci USA 2010, 107:20798-20803. 10.1073/pnas.1008076107, 2996458, 21071676.
54. Sato K, Izumi T, Misawa N, Kobayashi T, Yamashita Y, Ohmichi M, Ito M, Takaori-Kondo A, Koyanagi Y. Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice. J Virol 2010, 84:9546-9556. 10.1128/JVI.00823-10, 2937654, 20610708.
55. De Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJD, Chau TNB, Hoang DM, Chau NVV, Khanh TH, Dong VC, Qui PT, Cam BV, Ha DQ, Guan Y, Peiris JSM, Chinh NT, Hien TT, Farrar J. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercyto-kinemia. Nat Med 2006, 12:1203-1207. 10.1038/nm1477, 16964257.
56. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami M, Bartenschlager R, Liang TJ. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005, 11:791-796. 10.1038/nm1268, 2918402, 15951748.
57. Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, Shimotohno K. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005, 19:111-122. 10.1016/j.molcel.2005.05.014, 15989969.
58. Clapham PR, Weiss RA, Dalgleish AG, Exley M, Whitby D, Hogg N. Human immunodeficiency virus infection of monocytic and T-lymphocytic cells: receptor modulation and differentiation induced by phorbol ester. Virology 1987, 158:44-51. 10.1016/0042-6822(87)90236-4, 3107214.
59. Akari H, Mori K, Terao K, Otani I, Fukasawa M, Mukai R, Yoshikawa Y. In vitro immortalization of Old World monkey T lymphocytes with Herpesvirus saimiri: its susceptibility to infection with simian immunodeficiency viruses. Virology 1996, 218:382-388. 10.1006/viro.1996.0207, 8610465.
60. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg 1938, 27:493-497.
61. Macken C. Design and analysis of serial limiting dilution assays with small sample sizes. J Immunol Methods 1999, 222:13-29. 10.1016/S0022-1759(98)00133-1, 10022369.
62. Efron B. Bootstrap Method: Another Look at the Jackknife. Annals of Statistic 1979, 7:1-26.
63. Efron B, Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci 1986, 1:54-75.